Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Shanghai MicroPort Endovascular MedTech (Group) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 69.68%.
SHSE:688016's ROC (Joel Greenblatt) % is ranked better than 95.11% of 838
companies
in the Medical Devices & Instruments industry
Industry Median: 4.64
vs SHSE:688016: 78.87
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688016 vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Shanghai MicroPort Endovascular MedTech (Group) Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai MicroPort Endovascular MedTech (Group) Co ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 69.68% mean?
Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) has a ROC (Joel Greenblatt) % of 69.68% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co and its competitors. This is 50% below median its historical median of 140.42. Over the past decade, Shanghai MicroPort Endovascular MedTech (Group) Co's ROC (Joel Greenblatt) % has ranged from 78.87 to 267.96. According to the industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #41 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 4.9%.
Is Shanghai MicroPort Endovascular MedTech (Group) Co's ROC (Joel Greenblatt) % too high?
Shanghai MicroPort Endovascular MedTech (Group) Co's current ROC (Joel Greenblatt) % of 69.68% is 50% below median its 10-year median of 140.42. Over the past 10 years, this metric has ranged from a low of 78.87 to a high of 267.96. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.64. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 69.68% is 1401.7% above this industry median. Based on the distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #41 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai MicroPort Endovascular MedTech (Group) Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai MicroPort Endovascular MedTech (Group) Co's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #41 out of 838 companies for ROC (Joel Greenblatt) %. This places Shanghai MicroPort Endovascular MedTech (Group) Co in the top 5% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.64. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 69.68% is 1401.7% above this benchmark. Historically, Shanghai MicroPort Endovascular MedTech (Group) Co's own ROC (Joel Greenblatt) % has ranged from 78.87 to 267.96 over the past decade. While the company's 10-year median is 140.42 vs. the industry median of 4.64, Shanghai MicroPort Endovascular MedTech (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.64, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai MicroPort Endovascular MedTech (Group) Co's current ROC (Joel Greenblatt) % of 69.68% is 1401.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai MicroPort Endovascular MedTech (Group) Co's current ROC (Joel Greenblatt) % is 69.68%, which is 50% below median its own 10-year median of 140.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai MicroPort Endovascular MedTech (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥112.32, compared to a current price of ¥94.30 — trading 16% below its estimated fair value. The current ROC (Joel Greenblatt) % is 69.68%, which is 50% below median its 10-year median of 140.42 and 1401.7% above the Medical Devices & Instruments industry median of 4.64. Shanghai MicroPort Endovascular MedTech (Group) Co's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016), the current ROC (Joel Greenblatt) % is 69.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co stock appears to be undervalued.
The current stock price of Â¥94.30 is trading 16% below its estimated GF Value™ of Â¥112.32.
GuruFocus considers Shanghai MicroPort Endovascular MedTech (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:688016:
ROC (Joel Greenblatt) %: 69.68% (50% below median its 10-year median of 140.42)
GF Value™: Â¥112.32 vs. price of Â¥94.30 (16% below fair value)
Industry Position: 1401.7% above the Medical Devices & Instruments median (#41 of 838)
No single metric tells the full story. See the SHSE:688016 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Microport Endovascular Medtech Co Ltd is engaged in the Research, development, production and sales of interventional medical devices for the aorta and peripheral blood vessels.
97GF Score
Get the complete analysis for SHSE:688016
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688016 has been successfully added to your 
